Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ANVS | PRESS-RELEASE | bearish | 6/10 | Annovis Bio reported Q1 2026 EPS of -$0.63, significantly below the -$0.35 consensus estimate, with R&D expenses triplin | May 15, 2026 |
| PVLA | 8-K | neutral | 4/10 | Palvella Therapeutics announced new Phase 2 TOIVA trial data for QTORIN rapamycin in cutaneous venous malformations, pre | May 15, 2026 |
| BTAI | 8-K | neutral | 6/10 | BioXcel Therapeutics reported Q1 2026 revenue of $206K (up 22.6% YoY from $168K) and a GAAP net loss of $12.7M ($0.54/sh | May 15, 2026 |
| TRAW | 8-K | bearish | 7/10 | Traws Pharma reported Q1 2026 results with zero revenue and a net loss of $7.1M ($-0.53/share), a sharp reversal from th | May 15, 2026 |
| MSLE | 6-K | neutral | 5/10 | Satellos Bioscience reported Q1 2026 financial results showing a net loss of $9.8M ($0.53 per share), widening from $6.1 | May 15, 2026 |
| IBIO | 3 | neutral | 2/10 | Elizabeth Stoner filed a Form 3 initial statement of beneficial ownership with iBio, Inc. (IBIO), reporting no securitie | May 15, 2026 |
| MSLE | PRESS-RELEASE | neutral | 4/10 | Satellos Bioscience reported a Q1 2026 net loss of $9.8M ($0.53 per share), wider than the $6.1M loss a year ago, driven | May 15, 2026 |
| INDP | PRESS-RELEASE | bearish | 8/10 | Indaptus Therapeutics reported Q1 2026 results with a net loss of $2.5M ($0.23/share), improved from $4.5M ($9.11/share) | May 15, 2026 |
| PPBT | PRESS-RELEASE | neutral | 4/10 | Purple Biotech reported Q1 2026 net loss of $0.1M, significantly narrower than the $0.5M loss in Q1 2025, driven by $2.2 | May 15, 2026 |
| BTAI | PRESS-RELEASE | bearish | 6/10 | BioXcel Therapeutics reported Q1 2026 EPS of -$0.54 (GAAP) vs consensus -$0.48, a -12.5% miss, with IGALMI revenue of $2 | May 15, 2026 |
| TRAW | PRESS-RELEASE | mixed | 5/10 | Traws Pharma reported Q1 2026 results with a net loss of $7.1M (-$0.53 EPS, beating the -$0.56 consensus) and zero reven | May 15, 2026 |
| TIL | PRESS-RELEASE | neutral | 4/10 | Instil Bio reported Q1 2026 GAAP EPS of -$0.62, in line with the consensus estimate of -$0.59 (within the ±2% threshold) | May 15, 2026 |
| KYMR | PRESS-RELEASE | neutral | 4/10 | Kymera Therapeutics announced that KT-621 Phase 1b atopic dermatitis data will be presented at SID and ATS conferences, | May 15, 2026 |
| TARA | PRESS-RELEASE | bullish | 7/10 | Protara Therapeutics announced positive updated 12-month data from its Phase 2 ADVANCED-2 trial of TARA-002 in BCG-Naïve | May 15, 2026 |
| TLX | PRESS-RELEASE | neutral | 4/10 | Telix announced non-binding letters of intent to collaborate with EDAP TMS and Profound Medical, exploring the use of it | May 15, 2026 |
| KPTI | EFFECT | bearish | 7/10 | Two shelf registrations effective: a $400M universal shelf (including $100M ATM) and an 8.8M-share resale shelf. This en | May 15, 2026 |
| SPRY | 8-K | neutral | 5/10 | ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7M (up 184% YoY from $8.0M) and a net loss of $60.6M ($0.61/sh | May 15, 2026 |
| MENS | 20-F | bearish | 8/10 | Jyong Biotech's FY2025 20-F reveals a pre-revenue biotech in severe financial distress. The company has a net loss of $4 | May 15, 2026 |
| KZR | EFFECT | bearish | 5/10 | Kezar Life Sciences' registration statement on Form S-3 (File No. 333-284712) was declared effective by the SEC on May 1 | May 15, 2026 |
| SPRY | PRESS-RELEASE | bearish | 6/10 | ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7M, beating the $22.1M consensus, with neffy U.S. net product | May 15, 2026 |
| LGND | CLUSTER | neutral | 3/10 | Director John Kozarich and CLO Andrew Reardon sold a combined $155K in open-market sales on May 1, 2026, following Ligan | May 14, 2026 |
| PTGX | CLUSTER | neutral | 4/10 | Protagonist Therapeutics CEO Dinesh Patel sold $7.5M worth of stock on May 12, 2026, following a $600K sale by Director | May 14, 2026 |
| STTK | CLUSTER | neutral | 3/10 | Two senior executives at Shattuck Labs (CMO and CTO) sold a combined $212K in open-market shares on May 12, 2026, one we | May 14, 2026 |
| PRTA | 3 | neutral | 2/10 | William P. Scully filed a Form 3 initial statement of beneficial ownership, disclosing 736,000 ordinary shares held dire | May 14, 2026 |
| UTHR | CLUSTER | neutral | 4/10 | A cluster of insider sales at United Therapeutics (UTHR) totaling $1.72M occurred within 8 days of a Q1 2026 earnings re | May 14, 2026 |
| LODE | CLUSTER | bullish | 6/10 | Two Comstock Inc. insiders, including CEO Corrado DeGasperis and Director Steven Yu-Tsung Pei, made open-market purchase | May 14, 2026 |
| RPRX | 144 | neutral | 2/10 | Gregory Norden, an officer of Royalty Pharma, filed a Form 144 on May 14, 2026, indicating intent to sell 3,045 shares o | May 14, 2026 |
| LTRN | 8-K | bearish | 7/10 | Lantern Pharma entered into a securities purchase agreement to raise approximately $4.4 million through the sale of shar | May 14, 2026 |
| GYRE | 8-K | neutral | 5/10 | Gyre Therapeutics filed an 8-K furnishing an investor presentation under Item 7.01, to be presented at a scientific conf | May 14, 2026 |
| LIXT | PRESS-RELEASE | neutral | 3/10 | Lixte Biotechnology filed its Q1 2026 10-Q, reporting an EPS of -$0.27 with no consensus estimate available. The press r | May 14, 2026 |